Document Detail


Triple (interferon, ribavirin, amantadine) versus double (interferon, ribavirin) re-therapy for interferon relapser genotype 1b HCV chronic active hepatitis patients.
MedLine Citation:
PMID:  12699845     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Retreatment for 6 months with the association ribavirin-interferon of HCV-related chronic active hepatitis relapser patients has high probability of failure, mostly in those with genotype 1b. We evaluated the efficacy of extending the therapy from 6 to 12 months without or with the addition of amantadine. METHODS: Forty-nine genotype 1b relapser patients were treated with 3 MU of IFN-alpha2b three times per week and ribavirin 1000-1200 mg daily (double therapy). Twenty-four patients, who did not respond after 6 months of treatment, were randomized to continue for further 6 months either with the same schedule or with also the addition of amantadine 200 mg daily (triple therapy). RESULTS: A sustained virological response was observed in 15/37 subjects (41%) treated for 12 months of double therapy. In the arm of the study evaluating amantadine, end of treatment virologic response was observed in 0/12 patients of double therapy group and in 4/12 of triple therapy (P=0.09). After 6 months of follow-up, a sustained virologic response (SVR) was observed in two patients treated with the triple therapy. CONCLUSIONS: This study confirms poor results of retreatment (even if 12 months double or triple therapy) in relapser patients with HCV hepatitis, genotype 1b. No gain was obtained in prolonging from 6 to 12 months the standard double therapy, while triple therapy with amantadine as an additional regimen for this difficult subgroup of patients showed some cases of SVRs: amantadine addition deserves to be evaluated in larger trials.
Authors:
Guido Piai; Pietro Rocco; Maria Teresa Tartaglione; Angela Ciarleglio; Rosaria Focareta; Enzo Grimaldi; Fioravante Ievoli; Donato Iuliano; Maria Pacelli; Giovambattista Forte
Related Documents :
18474495 - Impact of switching virologically suppressed, hiv-1-infected patients from twice-daily ...
19826275 - Equally poor outcomes to pegylated interferon-based therapy in african americans and hi...
10803635 - Chronic hepatitis c: retreatment of relapsers. an evidence-based approach.
20600025 - Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with ch...
20120395 - Quality of life after colorectal cancer surgery in patients from university clinical ho...
22046705 - Effect of orthodontic appliances on oral microbiota--6 month follow-up.
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  Hepatology research : the official journal of the Japan Society of Hepatology     Volume:  25     ISSN:  -     ISO Abbreviation:  Hepatol. Res.     Publication Date:  2003 Apr 
Date Detail:
Created Date:  2003-Apr-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9711801     Medline TA:  Hepatol Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  355-363     Citation Subset:  -    
Affiliation:
Chronic Liver Disease Sub-Unit, Gastroenterology and Endoscopy Unit, AORN San Sebastiano, U.O.C., Azienda Ospedaliera San Sebastiano, via Palasciano, 81100, Caserta, Italy
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  VEGF gene therapy for coronary artery disease and peripheral vascular disease.
Next Document:  Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genot...